Caricamento...

Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer

KRAS mutations are associated with tumor resistance to EGFR TKIs (erlotinib, gefitinib) and to monoclonal antibody against EGFR (cetuximab). Targeted treatment of mutated RAS patients is still considered as a challenge. Inhibitors of c-Met (onartuzumab or tiwantinib) and MEK (selumetinib—a dual inhi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Exp Med
Autori principali: Nicoś, Marcin, Krawczyk, Paweł, Jarosz, Bożena, Sawicki, Marek, Szumiłło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2015
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844634/
https://ncbi.nlm.nih.gov/pubmed/25902737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10238-015-0349-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !